Chapter 24: PT-141 (Bremelanotide) and the Sexual Function Peptides

"In the fields of observation, chance favors only the prepared mind." — Louis Pasteur, lecture at the University of Lille (1854)

Overview

This chapter is about a family of peptides that does three apparently unrelated things — it darkens skin, it suppresses appetite, and it influences sexual desire — and it does all three through the same small set of receptors. That is not a coincidence to be explained away. It is the cleanest available demonstration of the principle Chapter 2 built the book on: a peptide's effect is determined by which receptor is listening and which tissue that receptor sits in, not by anything intrinsic to the molecule. One family, five receptor subtypes, three completely different clinical stories.

It is also a chapter about an accident. The compound that became an approved treatment for a sexual desire disorder came out of a research program aimed at producing a tan without ultraviolet light. The program worked, in a sense — it produced a compound that tans people, and that compound is now sold without approval on the internet, and it carries a safety signal that deserves your attention. The same research line also produced a narrowly approved, genuinely useful drug for a rare and painful photosensitivity disorder. Three destinations, one origin.

The section that matters most is §24.3, and it is worth flagging now. There is a widespread and consequential confusion between drugs that act on blood flow and drugs that act on desire. These are different components of sexual function, they involve different tissues, they respond to different molecules, and a person whose difficulty lies in one is not helped by a drug aimed at the other. This confusion costs people real time and real money, and it is fixable in about two paragraphs of clear anatomy.

A word on how this chapter is written. Sexual dysfunction is a legitimate medical problem that degrades quality of life, strains relationships, and is chronically under-discussed in clinical encounters because both parties find the subject awkward. It gets treated here the way any other functional complaint would be treated — clinically, specifically, and without commentary on the people who have it. No jokes. The subject is embarrassing enough for patients without a textbook adding to it.

This chapter also closes Part IV. The neuropeptides and social peptides have been, as a group, a series of near-misses: molecules with beautiful, well-mapped physiology whose translation into medicine has been repeatedly frustrated by delivery, by dose, and by the gap between a mechanism and an outcome. Bremelanotide is the part's one clear approval, and looking closely at what that approval actually says — and does not say — is the right way to end.

In this chapter, you will learn to:

• Explain how a tanning program produced a sexual-function drug, and why that history is the reason three different compounds share one receptor family
• Map MC1R through MC5R onto tissues and predict, from the map, what a nonselective agonist will do
• State the difference between a central desire mechanism and a peripheral vascular one, and use it to sort claims you encounter
• Report the bremelanotide approval with its real boundaries: premenopausal women, a specific diagnosis, validated instruments, a modest effect, and common nausea
• Argue both sides of the HSDD medicalization debate well enough that a proponent of either would accept your summary
• Distinguish afamelanotide's narrow legitimacy from melanotan II's unregulated use, and explain the melanoma concern at the correct strength — a signal, not a quantified risk
• Place kisspeptin correctly as established physiology with early clinical work

Learning Paths

💊 GLP-1 — §24.2 is your section. The melanocortin system is where MC4R lives, and MC4R is the receptor Chapter 13 spent its whole length on. Reading it again from the sexual-function side shows you why appetite drugs in this family carry pigmentation warnings. 🏋️ Performance — §24.6 is the one to read closely. Melanotan II is a gray-market compound with a real safety signal, and the reasoning that gets you there is the same reasoning you will apply to everything in Part VI. 🔬 Science — read straight through. §24.2 and §24.7 are the receptor pharmacology and the upstream reproductive physiology respectively, and §24.7 is the chapter's frontier. 💄 Cosmetic — §24.5 and §24.6 are written for you, and they are the chapter's sharpest contrast: an approved melanocortin drug used for a rare disease and an unapproved one used for a tan. The difference is not the molecule. 🏥 Clinical — §24.3 and §24.4 in full. §24.3 is the distinction patients most often arrive having gotten backwards, and §24.4 is a case study in reporting an approval honestly.

24.1 A tanning program that found something else

Pharmacology has a modest number of genuinely good accidents, and this is one of them.

The starting problem was cosmetic and, secondarily, medical. Ultraviolet light causes tanning by stimulating melanocytes — the pigment-producing cells in the skin — to make more melanin. Ultraviolet light also causes DNA damage, photoaging, and skin cancer. So the question a research program can reasonably ask is: can you get the melanocyte to do its job without the ultraviolet?

The natural signal that tells a melanocyte to make pigment is a peptide. It is called alpha-melanocyte-stimulating hormone, or α-MSH, and it is cut out of a larger precursor protein called proopiomelanocortin — POMC — which you have already met in Chapter 13 as the source of the appetite-suppressing signal in the hypothalamus. The same precursor yields α-MSH, ACTH, and β-endorphin, depending on where it is processed and by which enzymes. This is one precursor doing several unrelated jobs, and it is the first hint that the melanocortin system is going to resist tidy description.

Natural α-MSH is a poor drug. It is degraded quickly, and it is not selective. So the research program did what Chapter 4 says every peptide program does: it made analogs. It substituted residues to resist proteolysis, it cyclized the molecule to lock in a shape, and it introduced a D-amino acid — the mirror-image form that human proteases handle badly, since every enzyme in you evolved against the L-forms Chapter 1 cataloged. The result was a family of short, cyclic, protease-resistant melanocortin agonists that were much more potent than the natural hormone and lasted far longer.

They tanned people. That part worked.

And during that work, unexpected effects on sexual arousal were observed in some individuals receiving melanocortin analogs. This was not what anyone was looking for. It was noticed, it was taken seriously, and a separate development program followed — one aimed specifically at sexual function rather than at pigmentation. That program eventually produced bremelanotide, known during development as PT-141.

The compound that became bremelanotide came out of a tanning program. That sentence is worth sitting with, because it explains almost everything strange about this chapter: why an approved sexual medicine and an internet tanning compound are chemical near-relatives, why the sexual drug's label mentions skin darkening, and why the appetite chapter and this one share a receptor.

There is an origin anecdote attached to this history involving a self-administered dose and an unexpected result, and it circulates widely. Treat it the way you would treat any other single uncontrolled observation: it is the sort of thing that generates a hypothesis and cannot possibly settle one. Chapter 5 §5.2 gave you the rule, and it applies to charming stories exactly as it applies to unflattering ones. What makes this history credible is not the anecdote. It is that the observation was followed by a development program, and the development program ran randomized trials, and the trials are what we will actually look at in §24.4.

🧬 The Molecule — bremelanotide, and its very close relative

Bremelanotide is a cyclic heptapeptide — seven amino acids, joined end to end and then stapled into a ring by a bridge between two side chains. It weighs roughly 1,025 Da, which puts it near the small end of the peptide range on Chapter 1's size spectrum, comparable to oxytocin.

Three structural features, each doing a specific job:

Cyclization. The ring is closed by a lactam bridge between an aspartate side chain and a lysine side chain — an amide bond formed between two side chains rather than along the backbone. This is a different staple from the disulfide bond that holds insulin together, and it is more chemically robust. Cyclization locks the molecule into roughly one shape, which both raises potency (the receptor does not have to pay an entropic penalty to organize a floppy ligand) and slows degradation (proteases prefer extended, accessible backbones).

A D-amino acid. One residue is a D-phenylalanine rather than the L-form. Human proteases are stereospecific; a D-residue in the chain is a speed bump they were never built for.

A non-standard residue. The chain includes norleucine, which is not one of Chapter 1's twenty. Synthetic peptides are not restricted to the biological alphabet, and Chapter 32 shows why that freedom is one of the field's real advantages.

Now the part that matters for the rest of the chapter. Melanotan II — the unapproved tanning compound of §24.6 — is the same cyclic heptapeptide with a different C-terminus. Bremelanotide is, structurally, the free-acid form of the molecule whose amide form is melanotan II. One functional group at one end of a seven-residue ring.

That single change shifts the balance of receptor subtype activity — which, as §24.2 is about to show, is the difference between a drug that mostly affects the brain and a drug that substantially affects skin. An approved medicine and a gray-market tanning agent, separated by a terminal group. Chapter 1's lesson that the word "peptide" carries no evidentiary weight has a sharper version here: even near-identity carries no evidentiary weight.

24.2 Five receptors, three physiologies

The melanocortin system runs on five receptor subtypes, numbered MC1R through MC5R. They are all G-protein-coupled receptors, they all respond to melanocortin peptides, and they sit in different tissues doing different things. Learning the map takes about ninety seconds and pays for itself immediately.

THE MELANOCORTIN RECEPTOR FAMILY — one ligand family, five listeners

  RECEPTOR   PRINCIPAL TISSUE            WHAT ACTIVATION DOES
  ────────   ────────────────────────    ────────────────────────────────────────────
  MC1R       melanocytes (skin, hair)    shifts pigment production toward eumelanin
                                         → skin and hair darken; moles may darken
  MC2R       adrenal cortex              responds to ACTH, not to MSH; cortisol output
                                         (essentially outside this chapter)
  MC3R       CNS (hypothalamus), some    energy balance; feeding; a contributor to
             peripheral tissues          sexual function in animal models
  MC4R       CNS (hypothalamus,          appetite suppression and energy expenditure
             brainstem, spinal cord)     (Chapter 13) AND sexual arousal pathways
  MC5R       exocrine glands, sebaceous  sebum and exocrine secretion
                                         (minor clinical role so far)

  A NONSELECTIVE AGONIST HITS SEVERAL OF THESE AT ONCE.
  That is not a side effect in the usual sense. It is the map working as drawn.

Read that table forward and it is a list of tissues. Read it backward and it is a prediction engine. Give someone a melanocortin agonist with meaningful MC1R activity and you should expect pigmentation changes — not as an unfortunate surprise, but as the direct consequence of activating the receptor whose job is pigmentation. Give them one with MC4R activity and you should expect effects on appetite and on sexual arousal, because both pathways run through MC4R-expressing neurons.

This is the point where Chapter 13 and Chapter 24 shake hands. Chapter 13 is the owner of MC4R and appetite: it covered the genetics of MC4R deficiency, the role of the POMC/AgRP circuit in the arcuate nucleus, and setmelanotide, the MC4R agonist approved for specific rare genetic obesity syndromes. If you have read it, you already know something that belongs in this chapter — setmelanotide's known adverse effects include skin hyperpigmentation and darkening of existing moles. An obesity drug that tans people. Not because anything went wrong, but because you cannot activate MC4R with a peptide-like agonist without some MC1R activity coming along, and MC1R lives on melanocytes.

The same logic runs in reverse, and it appears on bremelanotide's label: focal hyperpigmentation is a recognized adverse effect of bremelanotide, more likely with more cumulative exposure, and more noticeable in people with darker baseline pigmentation. A sexual-function drug that darkens skin. Again: not a mystery. The map, working as drawn.

Bremelanotide is described as a melanocortin receptor agonist with activity at MC4R and at other subtypes — it is not a clean, single-subtype tool. Its central effects are attributed principally to MC4R and MC3R signaling in the hypothalamus; its pigmentation effects to residual MC1R activity. Melanotan II sits further toward the MC1R end of the same continuum, which is precisely why it tans more and why it is what gray-market sellers reach for.

🧬 The Molecule — where "who is listening" stops being a metaphor

Chapter 2 made the claim that a peptide has no intrinsic effect — that the effect is a property of the receptor and the tissue, and the ligand is only the key. That claim can feel like a philosophical flourish until you meet a system where it is literally, tediously true.

Here is that system. One family of endogenous peptides, derived from one precursor protein, produces skin pigmentation, adrenal steroid output, appetite suppression, sebum production, and sexual arousal. Nothing about α-MSH "is" a pigmentation signal. It is a pigmentation signal in skin because skin expresses MC1R. It is an appetite signal in the hypothalamus because the hypothalamus expresses MC4R. Move the same molecule to a different tissue and you get a different physiology, with no change to the molecule at all.

This has a direct practical consequence for how you read claims. When someone tells you a peptide "regulates" something — inflammation, recovery, aging, libido — the sentence is incomplete until it names a receptor and a tissue. Very often, pressing for that detail is enough to end the conversation, because the claim was assembled from a receptor's name and an organ's name with no evidence that the two were ever connected in a human being.

And notice the flip side, which is the more sophisticated error: knowing the receptor map perfectly would still not tell you whether an MC4R agonist helps a specific patient with a specific complaint. The map tells you what is plausible. Chapter 5's rule 3 — never upgrade a rating with mechanism — exists precisely because maps this satisfying are so easy to mistake for evidence.

🔍 Check Your Understanding

1. Setmelanotide is approved for certain rare genetic obesity syndromes and causes skin hyperpigmentation. Using only the receptor map, explain why — and say whether "side effect" is the right description.
2. A product is advertised as a "melanocortin peptide for libido, with the bonus of a natural tan." Is the "bonus" evidence that the product is sophisticated, or evidence that it is nonselective?
3. Why is it insufficient to say a peptide "acts on the melanocortin system"?

24.3 Desire and blood flow are not the same problem

This is the section worth getting right, and if you retain one thing from this chapter, make it this.

Sexual function is not a single variable. It is at minimum a set of partly independent components: desire (interest, motivation, the wish to engage), arousal (the physiological response, including genital blood flow), orgasm, and absence of pain. A person can have any one of these impaired with the others intact. Someone can have entirely normal genital vascular response and no interest whatsoever. Someone else can have strong desire and an inadequate physical response. These are different complaints with different mechanisms, and — this is the operative point — different drug classes.

TWO DRUGS, TWO PLACES, TWO PROBLEMS

  PDE5 INHIBITORS (sildenafil and relatives)     BREMELANOTIDE
  ─────────────────────────────────────────      ──────────────────────────────────────
  WHERE      peripheral — genital vasculature    central — hypothalamic circuits
  TARGET     phosphodiesterase type 5, an        melanocortin receptors on neurons
             enzyme inside smooth muscle cells   (MC4R, MC3R and others)
  WHAT       prevents breakdown of cGMP, so      modulates the neural signaling
             smooth muscle stays relaxed and     associated with sexual motivation
             blood flow is sustained
  RESULT     a better physical response TO       an effect on the interest itself
             arousal that is already occurring
  IF THE     ✔ helps                              ✘ not the target
  PROBLEM
  IS FLOW
  IF THE     ✘ not the target                     ✔ the target
  PROBLEM
  IS DESIRE

  A vascular drug cannot manufacture interest. A central drug cannot open a blood vessel.

Take the left column first, because most readers know it best. PDE5 inhibitors work downstream of arousal. The physiological chain is: sexual stimulation → nitric oxide release in genital tissue → production of cyclic GMP → smooth muscle relaxation → increased blood flow. An enzyme called phosphodiesterase type 5 degrades cyclic GMP and thereby ends the response. Inhibit that enzyme and the signal persists longer. Notice what this requires: the chain has to have started. A PDE5 inhibitor does not initiate anything. It sustains a response that arousal has already begun. This is why the class is prescribed with the instruction that sexual stimulation is necessary — not as a euphemism, but as a statement about where in the pathway the drug acts.

Now the right column. Bremelanotide acts centrally. It is not doing anything to a blood vessel. It is acting on melanocortin receptors in hypothalamic circuits involved in sexual motivation, and its intended effect is on desire — the upstream, motivational component. Whether it succeeds, and by how much, is §24.4's problem. But the place it acts is settled, and it is not the place a vascular drug acts.

These two are therefore not interchangeable, and not competitors, and not versions of each other. A person whose difficulty is a vascular one gets nothing useful from a central desire drug. A person whose difficulty is absent desire gets nothing useful from a vascular drug — the plumbing was never the problem. The commonest version of this error in practice is a person with a desire complaint who tries or is offered a PDE5 inhibitor, finds it does nothing, and concludes that their problem is untreatable or imaginary. It is neither. It was the wrong target.

💊 In the Clinic — the question that sorts this out

Clinicians who work in this area do not begin with a drug. They begin with a distinction, and the distinction is usually made by asking, in some form: is the interest there and the response missing, or is the interest itself absent?

That single question separates a vascular complaint from a desire complaint, and it points at entirely different evaluations. A response problem prompts questions about cardiovascular health, diabetes, medications, and hormones — because inadequate genital blood flow is frequently the first visible sign of vascular disease elsewhere, and treating it as a bedroom issue can mean missing an early cardiovascular warning. A desire problem prompts an entirely different inventory: relationship context, mood, sleep, medications (antidepressants are a common and reversible contributor), pain, life circumstances, and whether the change is lifelong or acquired, situational or global.

Two features of that inventory deserve emphasis. Most desire complaints have a contributing cause that is not a receptor. And the single most common pharmacological contributor is a medication the person is already taking, which is a fixable problem that no new peptide addresses.

This is the reason a book cannot substitute for a clinician here, and it is not a disclaimer. A textbook can tell you the difference between a central and a peripheral mechanism. It cannot tell you which one you have, and getting that wrong is the most expensive mistake available in this whole area.

⚠️ Hype Check — "the female Viagra"

The claim, in its usual form:

"Bremelanotide is the female version of Viagra."

This phrase has appeared in headlines, in marketing, and in a great deal of casual conversation. It is wrong in three separate ways, and each one matters.

Wrong about mechanism. Sildenafil acts peripherally on vascular smooth muscle; bremelanotide acts centrally on neural circuits. They are not analogous drugs pointed at different sexes. They are different drugs pointed at different components of sexual function. Calling one the female version of the other implies a parallel that does not exist at any level of the biology.

Wrong about the target complaint. Sildenafil's approved use addresses a response problem. Bremelanotide's approved use addresses a desire problem. Those are different diagnoses. A phrase that merges them teaches the exact confusion §24.3 exists to prevent.

Wrong about the magnitude, which is the most damaging part. The comparison imports an expectation. PDE5 inhibitors produced a large, obvious, easily perceived effect in their responder population — the kind of effect that does not require an instrument to detect. Bremelanotide's trial effect was statistically significant and modest, measured on questionnaires. Setting up the first as the template for the second guarantees disappointment, and disappointment in this area tends to be interpreted by patients as personal failure rather than as a mis-set expectation.

Verdict: an analogy that is wrong about site of action, wrong about indication, and wrong about effect size. It survives because it is short. Chapter 5's insistence that a rating names a population and an endpoint is, among other things, a defense against this kind of headline.

24.4 The approval: narrow population, real evidence, modest effect

Bremelanotide is approved, under the brand name Vyleesi, for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as needed, in anticipation of sexual activity, rather than taken daily. Those are the boundaries of the approval, and this section is about reading them carefully.

Three things have to be said plainly, and a chapter that omits any of them is not reporting the approval honestly.

First: the approved population is narrow, and the exclusions are specific. The indication covers premenopausal women with acquired, generalized HSDD. It does not cover postmenopausal women. It does not cover men. It does not cover low desire attributable to a coexisting medical or psychiatric condition, to relationship difficulties, or to the effects of another medication. Those exclusions are not fine print. They are a description of who was actually studied — and Chapter 8's refusal to extend a cardiovascular outcome to a primary-prevention population it had not been tested in is the same discipline applied to a different drug.

Second: the effect size was statistically significant and modest. The pivotal evidence comes from two identically designed randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD. The co-primary endpoints were changes on validated instruments — a desire domain score and a distress measure specifically concerning low desire. On both, the bremelanotide groups improved more than placebo, and the differences reached statistical significance. The differences were also small in absolute terms: fractions of a point on scales spanning several points, with substantial placebo response in both trials. Notably, the trials did not demonstrate an increase in the number of satisfying sexual events — an endpoint that was examined and that did not separate from placebo.

Third: nausea is common, and for this drug that is not a footnote. Nausea was reported by a large minority of participants — on the order of four in ten in the trial population — most often with the first exposure and often decreasing thereafter. Flushing, headache, and injection-site reactions were also common. There are transient blood pressure and heart rate changes, which is why the label carries a contraindication in uncontrolled hypertension and in known cardiovascular disease. And, per §24.2, focal hyperpigmentation occurs.

Sit with the practical shape of that. This is a drug taken in anticipation of sexual activity, and its most common adverse effect is nausea. Even at a low individual probability, the prospect of nausea in that specific context is a meaningful practical limitation, and it plainly contributes to the real discontinuation rates seen with the drug. An adverse effect's importance is not captured by its frequency alone; it depends on what the drug is for.

🔬 Read the Study — what a validated instrument buys you, and what it costs

The bremelanotide trials measured desire and distress with validated questionnaires. This is standard, defensible, and worth understanding, because instrument choice is where a great deal of sexual-medicine evidence is won and lost.

Why not just measure events? Because frequency of sexual activity is a poor proxy for the thing the diagnosis is about. A person can have frequent sex and no desire. A person with high desire may have no available partner. Counting events measures circumstance at least as much as it measures physiology, and it is influenced by a partner whose behavior is not randomized.

So investigators use instruments — questionnaires with defined items, tested for internal consistency, test-retest reliability, and correlation with clinician assessment. This is a real methodological achievement and it makes trials possible in a domain with no blood test.

What it costs you is interpretability. When a trial reports a between-group difference of a fraction of a point on a desire domain, you are entitled to ask a question that has no easy answer: what does that feel like? The bridge concept is the minimal clinically important difference — the smallest change a patient would notice and value. It is estimated, contested, and instrument- specific, and when a trial's effect sits near it, reasonable people disagree about whether the drug does something patients care about.

The second cost is the placebo response, which in sexual-function trials is large. Entering a study, discussing the problem, having it taken seriously, and expecting help all improve scores. This is why uncontrolled reports in this area are near-worthless and why the placebo arm is the most informative column in the table.

How to read a trial like this in one pass: find the instrument and check it was validated; find the between-group difference, not the within-group change; compare it to any stated minimal important difference; check the placebo arm's movement; and check whether the behavioral endpoint — the thing outside the questionnaire — moved. Here, it did not.

HSDD: a diagnosis that requires distress, and a genuine argument about whether it should exist

Hypoactive sexual desire disorder is defined by persistently low or absent sexual desire that causes marked distress or interpersonal difficulty and is not better explained by another condition, a medication, or relationship circumstances.

The distress criterion does the essential work and is constantly dropped in popular coverage. Low desire that does not trouble the person is not a disorder. People with low desire who are content have a characteristic, not a diagnosis. The diagnosis exists to describe a person who is bothered by their own experience and wants it to change.

The diagnosis has been genuinely contested, and both sides deserve a fair hearing.

The critics' argument. Sexual desire varies enormously between people and across a life — naturally, and in response to stress, sleep, relationship duration, age, and a hundred other inputs. Constructing a diagnostic category around the low end of a normal distribution risks converting variation into pathology. Critics add a historical observation: the category has been actively promoted at moments when a drug was seeking a market, and disease-awareness campaigns funded by manufacturers have shaped both clinical and public understanding of how common the condition is. They note that a diagnosis defined partly by distress is vulnerable, because distress can be manufactured by telling people their desire is abnormal. And they point out that when low desire has a contextual cause — an unrewarding relationship, exhaustion, a partner's behavior — naming it a disorder in one person locates the problem in the wrong place.

The proponents' argument. Distressing low desire is real, common, and durable, and people who have it frequently describe it as a significant loss. Dismissing it as normal variation does not make it go away; it removes the person's standing to seek help and reproduces the long history of women's sexual complaints being treated as not-quite-medical. Proponents note that the distress criterion is not a loophole but a safeguard — it is exactly what prevents the diagnosis from capturing contented low desire. They observe that every criticism above applies equally to conditions we do not hesitate to treat, insomnia being the obvious parallel: sleep need varies, sleep complaints are context-sensitive, the diagnosis has been marketed, and none of that means people who cannot sleep should be turned away. And they point out that a person told their distressing complaint is merely normal variation has been handed a diagnosis of a different kind — that their unhappiness is their own fault.

Both arguments have force, and this is not a dispute that data alone can settle, because the underlying question is partly about where to draw a line rather than about where a fact lies. Chapter 12 established the framework: the same phenomenon can be described as disease, as behavior, or as environment, and the choice among those descriptions determines who is responsible, who pays, and what kind of help is offered. HSDD is Chapter 12's framework applied to desire instead of to weight, with the same stakes and the same absence of a purely empirical resolution.

What this book can do is insist that the argument stay separate from the evidence question. Whether HSDD should be a diagnosis is a debate about categories. Whether bremelanotide improved scores more than placebo in women who met the criteria is a question about trials, and it has an answer. Rule 4 of the rating system — never downgrade with distaste — exists for exactly this configuration. You are not entitled to rate the drug lower because you dislike the diagnosis.

📊 Evidence Rating

Claim: Bremelanotide improves sexual desire and reduces desire-related distress in premenopausal women meeting criteria for acquired, generalized hypoactive sexual desire disorder. Rating: ✅ Strong clinical evidence (as of this writing) Reason: Two randomized, double-blind, placebo-controlled trials in the target population using validated desire and distress instruments showed statistically significant improvement over placebo, supporting regulatory approval; the effect is modest, nausea is common, and the behavioral endpoint did not separate from placebo. What would change it: Failure to replicate in adequately powered independent trials; evidence that the instrument differences fall below a well-established minimal clinically important difference; or long-term data showing that discontinuation due to adverse effects is high enough that the population who benefits durably is negligible.

Now read that rating carefully, because it is doing a job. ✅ here means the evidence supports this claim in this population — that adequately designed trials were run, that they were positive on their prespecified primary endpoints, and that a regulator reviewing the full dataset agreed. It does not mean the drug is transformative. It does not mean most people who take it will notice a large change. It does not mean the effect is bigger than the placebo response, only that it is distinguishable from it.

If a ✅ in your mind means "this works dramatically," recalibrate now, because that miscalibration will distort every rating in the rest of the book. ✅ is a statement about evidential support, not about effect magnitude. Those are separate axes, and this drug is the clearest illustration in the book of a claim that scores high on the first and low on the second. A ⚠️ compound could in principle have a larger true effect than a ✅ compound; the difference between them is how well we know.

📊 Evidence Rating

Claim: Bremelanotide improves sexual function in men, or in postmenopausal women. Rating: ❌ Hype outpaces evidence for the claim as marketed — the approval does not extend here, and this population is best described as not rated by the approved evidence. Reason: These are not the studied or approved populations. Earlier development work in men exists but did not produce an approval, and postmenopausal women were not part of the pivotal program; extending an efficacy conclusion beyond the population in which it was demonstrated is an inference, not a finding. What would change it: Adequately powered randomized trials in each population with prespecified endpoints, plus safety data in populations with a different baseline cardiovascular risk profile.

This is the same refusal Chapter 8 made when it declined to extend a cardiovascular outcome result to a population that had not been studied, and it is one of the most reliably useful habits in the book. An approval is a statement about a population. Marketing, telehealth prescribing, and gray-market sale all routinely extend a compound past that boundary while continuing to cite the trials that established it inside the boundary. Chapter 5's rule 6 — one molecule, many ratings — is not a technicality. It is the machinery that keeps a positive result from leaking into populations it never covered.

🩺 Safety and Risk — reading an as-needed drug's adverse effect profile

Adverse effects are usually presented as a list with percentages, which flattens something important: the same rate means different things depending on how a drug is used.

For a daily chronic medication, a common transient nausea that fades over the first week is often tolerable, because exposure is continuous and adaptation occurs. For a drug taken as needed, in anticipation of a specific event, the arithmetic is different. Each administration is a fresh first-exposure-like decision, the adverse effect lands in exactly the window the drug was taken to improve, and there is no adaptation curve to wait out if use is infrequent.

That is why the nausea rate reported in the bremelanotide trials — a large minority of participants — is a genuine practical limitation rather than a routine tolerability note, and why real-world persistence with the drug has been modest.

Three other label items worth knowing. Transient increases in blood pressure and decreases in heart rate occur after administration, which is why it is contraindicated in uncontrolled hypertension and in known cardiovascular disease. Focal hyperpigmentation can occur and may not fully resolve, which is MC1R doing its job (§24.2). And nausea severe enough to cause vomiting was reported by some participants, which matters for anyone using an oral medication whose absorption would be affected.

None of this is a reason not to use the drug. It is the information a person needs to decide whether the trade is worth it for them — which is a conversation with a prescriber who knows their history, and the subject of Chapter 39.

24.5 Afamelanotide: an approved drug for a rare and painful disease

The same research line produced a second approved medicine, and it is a much cleaner story.

Afamelanotide — also known as melanotan I — is a linear analog of α-MSH with high MC1R activity. It is approved to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP).

EPP deserves a real description, because the disease is what makes the drug make sense. It is a rare inherited disorder of heme synthesis, most often caused by reduced activity of the enzyme ferrochelatase. The consequence is accumulation of protoporphyrin IX in red blood cells and, from there, in the skin and its small blood vessels. Protoporphyrin IX absorbs visible light — notably in the violet-blue range — and when it does, it generates reactive species in the tissue around it.

What that produces is not a rash in the ordinary sense. Patients describe burning, stinging pain beginning within minutes of light exposure, escalating over hours, and lasting for days. It can be triggered by ordinary daylight, by light through window glass, and in some cases by strong indoor light. Conventional sunscreens, which are designed against ultraviolet, help little, because the offending wavelengths are visible.

The result is a life organized around avoiding light. Patients describe careful management of every outdoor activity, working at night, driving with the windows covered, and childhoods spent indoors. The condition is rare, was long under-recognized, and has historically had essentially no pharmacological treatment.

Afamelanotide addresses it exactly where §24.2 predicts. By agonizing MC1R, it drives melanocytes toward increased eumelanin — the pigment type that absorbs and dissipates light energy before it reaches the protoporphyrin below. It does not fix the enzyme deficiency and it does not clear protoporphyrin IX. It puts a photoprotective layer between the light and the molecule that reacts to it. The clinical endpoint in trials was correspondingly direct: time spent in direct sunlight without pain. It increased.

The drug is formulated as a slow-release subcutaneous implant rather than a conventional injection — a delivery choice driven by the peptide-pharmacokinetics problem Chapter 4 laid out, since a short, rapidly cleared peptide cannot maintain sustained MC1R signaling any other way.

📊 Evidence Rating

Claim: Afamelanotide increases pain-free light exposure in adults with erythropoietic protoporphyria. Rating: ✅ Strong clinical evidence (as of this writing) Reason: Randomized controlled trials in the target population showed increased pain-free time in direct sunlight, supporting regulatory approval in multiple jurisdictions; the mechanism, the endpoint, and the indication are aligned and narrow. What would change it: Failure of replication, post-marketing data showing the effect does not persist, or long-term melanocytic surveillance data revealing an unacceptable safety trade-off in chronic use.

Two features of that rating are worth naming.

It is narrow, and the narrowness is a strength. The claim covers one rare disease, one endpoint, one population. It says nothing about whether afamelanotide is useful for anything else, and its approval provides no support whatever for cosmetic melanocortin use. A narrow ✅ is often more trustworthy than a broad one, because the narrower the claim, the more likely the trial actually tested it.

It establishes that this receptor family can produce real medicine. That matters for §24.6, because the argument there is emphatically not "melanocortin agonists are bad." The argument is about a specific unapproved compound used for a cosmetic purpose in an unregulated way, and having a legitimate approved sibling on the table is what keeps that argument from collapsing into generalization.

💊 In the Clinic — why the same pharmacology is fine here and not there

A reasonable person could ask: if afamelanotide is approved and stimulates melanocytes, why is §24.6 about to be so cautious about melanotan II, which also stimulates melanocytes?

Four differences, and they are all about context rather than chemistry.

Indication. One treats a disease that causes severe pain and constrains a person's entire life. The other produces a cosmetic change in people who are well. The acceptable risk in those two situations is not the same number, and it should not be.

Supervision. Approved use occurs in specialist centers, with periodic skin examination built in — which means that if a melanocytic lesion changes, someone whose job it is to notice is looking. Unsupervised use has no such loop.

Product. An approved implant has an identity, a purity specification, and a manufacturer with a regulatory obligation. A vial bought online has none of those, and Chapters 19 and 34 document what that actually means in practice.

Evidence base. One has completed randomized trials and post-marketing surveillance. The other has neither.

Same receptor. Entirely different risk-benefit arithmetic. This is what people mean when they say the drug is not the same thing as the use of the drug.

24.6 Melanotan II: unapproved, widely used, and a genuine melanoma concern

Melanotan II is not approved as a medicine in any major jurisdiction. It is nonetheless widely sold and used for cosmetic tanning.

This section will describe what is known and what is not. It will not describe how the compound is used, because that is not what this book does — and in this instance the omission is not a formality. The relevant hazard is not associated with any particular technique; it follows from the pharmacology.

The concern, stated precisely. Melanotan II is a potent, nonselective melanocortin agonist with substantial MC1R activity. MC1R activation stimulates melanocytes. Melanocytes are the cell of origin of melanoma. Deliberately and repeatedly stimulating melanocyte activity and proliferation, in an unregulated way, without medical supervision, in people who may already carry elevated melanoma risk — many fair-skinned, many with substantial prior sun exposure, many drawn to the compound precisely because they want to look tanned — is a genuine theoretical hazard.

What is actually documented. There is a body of published case reports describing users of melanotan II with:

• rapid darkening and enlargement of existing melanocytic nevi (moles)
• eruption of new melanocytic lesions, sometimes in numbers, sometimes over a short period
• changes in nevi with atypical features on examination and on histology
• melanoma diagnosed in individuals with a history of melanotan II use

Alongside these, published reports describe other effects including nausea, flushing, and spontaneous erections, along with less common but more serious reports — rhabdomyolysis and renal complications among them.

Now the critical methodological point, and it is the reason this section exists in a book about evidence rather than a book about tanning.

WHAT A CASE REPORT CAN AND CANNOT DO           (the rule from Chapter 5 §5.2)

  FOR EFFICACY                             FOR RARE, DISTINCTIVE HARM
  ─────────────────────────────            ────────────────────────────────────
  Near-useless.                            Genuinely valuable.

  No control group. No blinding.           A distinctive event, temporally linked,
  Reporting is driven by success.          reported repeatedly by independent
  Regression to the mean and placebo       clinicians, is how most drug harms have
  response are unmeasurable.               historically first been detected.
  Publication requires only that           Nobody is going to run a randomized trial
  someone found it interesting.            of an unapproved cosmetic compound with
                                           melanoma as an endpoint.
  ───────────────────────────────────────────────────────────────────────────────
  WHAT THE MELANOTAN II REPORTS ESTABLISH:   a signal that warrants concern.
  WHAT THEY DO NOT ESTABLISH:                a quantified risk.

  "How much does this raise melanoma risk?" HAS NO ANSWER FROM THIS EVIDENCE.
  Neither does "it doesn't."

This is exactly the situation Chapter 5 §5.2 described, and the chapter should say so explicitly. The asymmetry it set out — case reports are near-useless for establishing that something works and genuinely valuable for detecting rare, distinctive harms — is not a rhetorical convenience. It follows from what the two inference problems require. Establishing efficacy requires knowing what would have happened otherwise, which a case series cannot supply. Detecting a distinctive harm requires noticing an unusual event in temporal association with an exposure, which is precisely what an alert clinician writing up an unusual case does supply.

So be exact about the strength of the conclusion. These reports establish a signal warranting concern. They do not establish a quantified risk. Nobody can tell you the number, and anyone who offers one is inventing it. The honest position is that a biologically coherent mechanism (melanocyte stimulation), a susceptible population (people who tan poorly and want to tan), and a set of independent clinical reports of melanocytic changes and melanoma all point the same direction — and that the size of the effect is unmeasured and, given the market, will likely remain so.

🩺 Safety and Risk — the second problem, which is the vial

Everything above concerns the pharmacology of melanotan II as a molecule. There is a second, entirely separate risk category that applies to any unapproved injectable purchased through unregulated channels, and Chapters 19 and 34 cover it in full.

Identity is not verified. Purity is not verified. Concentration is not verified. Sterility is not verified, and injectable products that are not sterile cause infections. Endotoxin content is not verified, and endotoxin causes fever and systemic reactions independent of anything the peptide does. Products labeled "for research use only" carry that phrase because it removes them from the regulatory framework that would otherwise require any of the above.

As Chapter 1 §1.7 noted, the documented harm in the unregulated peptide market has come disproportionately from contamination, wrong identity, and wrong concentration rather than from exotic toxicity of the intended molecule. That general pattern applies here in addition to the melanocyte-specific concern, not instead of it.

And a public health note that is not a moral one: the underlying motivation — a tan without ultraviolet exposure — is not irrational. UV exposure genuinely causes skin cancer, and wanting to avoid it is sound. The problem is that the proposed substitute has no efficacy or safety trials, has a mechanism that acts directly on the cell type melanoma arises from, and comes with a set of case reports pointing the wrong way. Cosmetic products that deposit color on the skin surface without touching a melanocyte are, whatever one thinks of them aesthetically, not implicated in any of this.

📊 Evidence Rating

Claim: Melanotan II is a safe and effective way to achieve cosmetic skin tanning. Rating: ❌ Hype outpaces evidence (as of this writing) Reason: Unapproved in every major jurisdiction; no completed randomized human trials establishing either efficacy or safety for this use; and a genuine melanoma concern supported by published case reports of changing nevi, eruptive melanocytic lesions, and melanoma in users. What would change it: Completed randomized controlled trials with adequate dermatologic surveillance and long-term follow-up, plus cohort or registry data large enough to quantify — or exclude — the melanocytic risk. Neither is plausibly forthcoming for an unapproved cosmetic compound.

⚠️ Hype Check — a ❌ with an unusual structure

Look closely at that rating, because it is built differently from most ❌ ratings in this book.

The standard ❌ is a statement about absence: animal data only, or preliminary human work, or trials that contradicted the popular claim. It says the confident version of this claim is not supported. It explicitly does not say the compound is harmful, and Chapter 5 was emphatic that ❌ compounds may later be shown to work.

This ❌ is reinforced by a safety signal rather than resting only on absent efficacy evidence. It is not merely that we lack trials showing melanotan II tans people safely — though we do. It is that the mechanism by which it works is direct stimulation of the cell type that gives rise to melanoma, and that independent clinicians have published cases of melanocytic change and melanoma in users. The absence of evidence and the presence of a signal point the same way.

That combination is uncommon, and it changes what the rating means practically. For a typical ❌ compound, the reasonable posture is: the case has not been made; wait for data. For this one, the reasonable posture is: the case has not been made, and there is a specific documented reason for concern that would need to be affirmatively resolved.

This does not violate rule 2 — ❌ still describes the evidence. It is just that here the evidence includes harm reports, and the rating summarizes all of it. It also does not violate rule 4: the rating is not a downgrade for distaste. Cosmetic tanning is a perfectly legitimate thing to want. The rating would be identical if the goal were noble, and it would improve tomorrow if the trials existed.

24.7 Kisspeptin: the switch upstream of everything

The chapter's last peptide operates in a different part of the system, and it is the frontier.

Kisspeptin is a peptide encoded by the KISS1 gene, acting on a receptor called KISS1R. Its position in the reproductive hierarchy is upstream — kisspeptin neurons in the hypothalamus stimulate the neurons that release GnRH (gonadotropin-releasing hormone), which drives the pituitary to release LH and FSH, which drive the gonads to produce sex steroids and gametes.

THE REPRODUCTIVE AXIS — and where kisspeptin sits

  KISSPEPTIN NEURONS (hypothalamus)
        │  generate and shape the pulsatile signal
        ▼
  GnRH NEURONS  ──► pulses of GnRH into the pituitary portal system
        │
        ▼
  ANTERIOR PITUITARY  ──► LH and FSH
        │
        ▼
  GONADS  ──► testosterone / estradiol, gametes
        │
        └──── feedback ────► back onto kisspeptin neurons, which is largely
                             how sex steroids regulate their own production

  Kisspeptin is not one more input among many. It is the layer that makes the
  pulsatile GnRH signal happen at all.

The evidence that kisspeptin is essential rather than merely contributory is genetic and unambiguous: loss-of-function mutations in KISS1R cause failure of puberty — a form of normosmic hypogonadotropic hypogonadism in which the gonads are intact and capable, the pituitary is intact and capable, and the upstream signal never arrives. That is about as clean a demonstration of necessity as human physiology offers, and it is why kisspeptin's discovery reorganized the field's understanding of how puberty starts.

There is also a link back to Chapter 3's central theme. GnRH must be pulsatile. Continuous GnRH receptor stimulation desensitizes the pituitary and shuts the axis down — which is not a laboratory curiosity but the therapeutic basis of an entire drug class (the -relin compounds of Chapter 1 §1.8, used in prostate cancer and elsewhere precisely because continuous stimulation suppresses). Kisspeptin neurons are central to generating that pulsatility. A peptide whose therapeutic potential depends on reproducing a rhythm is a peptide with a hard pharmacokinetic problem, and that constraint shapes everything about how kisspeptin is being investigated.

What is being studied. Kisspeptin and its analogs are under investigation in reproductive medicine — including as a physiological alternative for triggering egg maturation in assisted reproduction, where the hope is that a signal acting upstream produces a more self-limiting response than a direct downstream trigger. Separately, and at an earlier stage, research groups have examined kisspeptin administration in relation to sexual and emotional processing, using brain imaging alongside questionnaires, in both men and women — including small studies in people with distressing low desire. These are early-phase, small, mechanistically oriented studies. They are real science, conducted properly and published openly, and they are not a basis for clinical claims.

📊 Evidence Rating

Claim: Kisspeptin or kisspeptin analogs are effective treatments for reproductive or sexual disorders. Rating: 🔬 Frontier (as of this writing) Reason: The physiology is established and central — loss-of-function mutations in the receptor cause failure of puberty — but clinical work is early-phase and small, with mechanistic and imaging endpoints rather than outcomes, and no approved indication. What would change it: Adequately powered randomized trials with prespecified clinical endpoints in a defined population; toward ⚠️ if such trials are positive and preliminary, toward ✅ with replication and approval, and toward ❌ if larger trials fail to reproduce the early signals.

Kisspeptin is a useful counterweight to end the chapter on, because it is the honest version of what melanotan II's sellers pretend to have. Both involve real receptors and coherent physiology. One is being developed in the open, with registered trials, published negative findings, and no product for sale. The other is being sold. The presence of a beautiful mechanism is common to both; the presence of evidence is not. Rule 3 — never upgrade with mechanism — is what keeps you from being impressed by the wrong one.

🔍 Check Your Understanding

1. Why does the existence of KISS1R loss-of-function mutations causing failed puberty support a 🔬 rather than a ⚠️ or ✅ for kisspeptin as a treatment?
2. GnRH must be delivered in pulses to stimulate rather than suppress. What does that imply about the difficulty of turning an upstream peptide into a drug?
3. Kisspeptin and melanotan II both have well-described receptors and coherent mechanisms. Name the single feature that most sharply separates them as objects of evidence.

24.8 The group, rated

Five claims, four molecules, four different states of evidence. Read the table as a single argument about how ratings work.

Four observations about that table, each of which is really a lesson about the rating system.

One family, four ratings. Every molecule here works on closely related receptors. Two are structurally near-identical. If ratings attached to molecules — or worse, to families — this table would be one row and it would be wrong. Rule 1 exists because evidence lives at the level of a claim about a population and an endpoint, and nowhere else.

The two ✅s do not mean the same thing about magnitude. Afamelanotide's ✅ and bremelanotide's ✅ are identical statements about evidential support and quite different statements about what a patient experiences. Both rest on randomized trials in the target population and both are approved. That is what the symbol certifies. How much the drug does is a separate question you have to ask separately — and the chapter put "effect modest" in the table's own reason column so the two never get merged.

The two ❌s do not mean the same thing either. The bremelanotide row's ❌ is about an inference beyond the data — a positive result being carried into a population it never covered. The melanotan II row's ❌ is about an absence of data reinforced by a harm signal. Same symbol, different structure, different implication for what a reasonable person does next. This is the deepest reason the system requires a one-sentence reason on every rating: the symbol alone underdetermines the meaning.

Nothing here was rated on how it sounds. Cosmetic tanning gets a ❌ on evidence, not on taste — a well-run trial program could move it, in principle. HSDD treatment gets a ✅ on evidence, not on whether one finds the diagnosis persuasive. Rules 2 and 4 are mirror images, and this chapter is where they both get tested, because sexual function and cosmetic appearance are two of the topics where readers most reliably import a verdict before consulting the data.

📋 Your Evidence Dossier

This chapter fills Field 7 — Regulatory Status and Approved Indication — for a narrow approval.

Field 7 is where you record what a regulator has actually authorized, for whom, and for what. It is the shortest field in the workbook to fill and one of the two or three most useful, because it is the field that most often contradicts the impression a person has formed from everything else they have read. Appendix C has the blank form.

The lesson this chapter contributes is a single sentence, and it is worth writing at the top of the field:

Breadth of use is not breadth of approval.

The demonstration — bremelanotide

FIELD 7 — REGULATORY STATUS: BREMELANOTIDE          [worked demonstration]

  APPROVED?              Yes — United States (brand: Vyleesi)
  APPROVED INDICATION    Acquired, generalized hypoactive sexual desire disorder
                         (HSDD)
  APPROVED POPULATION    PREMENOPAUSAL WOMEN
  EXPLICITLY NOT COVERED postmenopausal women; men; low desire attributable to a
                         coexisting medical or psychiatric condition, to relationship
                         problems, or to the effects of a medication or substance
  ADMINISTRATION         as needed, in anticipation of sexual activity (not daily)
  ENDPOINTS THAT         validated desire domain score; validated desire-related
  SUPPORTED APPROVAL     distress score — both improved vs placebo, both modestly
  NOTABLE LABEL ITEMS    nausea common; transient BP increase / HR decrease;
                         contraindicated in uncontrolled hypertension and known
                         cardiovascular disease; focal hyperpigmentation possible
  ─────────────────────────────────────────────────────────────────────────────
  HOW IT IS DISCUSSED    "the female Viagra"; a libido drug; a men's performance
  AND SOLD IN PRACTICE   compound; "PT-141" sold as an unapproved research chemical
                         to anyone, for any purpose, in either sex
  ─────────────────────────────────────────────────────────────────────────────
  THE GAP                The approval is one diagnosis in one hormonal-status group.
                         The use is everything.

Now compare that with a second entry, where the same field looks superficially similar and means something quite different:

FIELD 7 — REGULATORY STATUS: MELANOTAN II            [worked demonstration]

  APPROVED?              No. Not approved as a medicine in any major jurisdiction.
  APPROVED INDICATION    None.
  APPROVED POPULATION    None.
  SOLD AS                a "research chemical," frequently with a not-for-human-use
                         label that is the legal mechanism permitting the sale
  EVIDENCE STATUS        no completed randomized human efficacy or safety trials
  SAFETY REPORTS         published case reports: darkening/enlarging nevi, eruptive
                         melanocytic lesions, melanoma in users; also nausea,
                         flushing, spontaneous erections; rarer serious reports
  ─────────────────────────────────────────────────────────────────────────────
  THE TRAP               Its approved relative (afamelanotide) and its structural
                         near-twin (bremelanotide) are both real approved drugs.
                         NEITHER approval transfers. Approvals do not run in families.

Step 1 — Fill Field 7 for every peptide in your dossier

For each one, answer four questions in this order, and resist the urge to soften any of them:

1. Is it approved anywhere by a recognized regulator? Yes or no. "Available from a clinic" is not an answer to this question. Neither is "used in Europe."
2. If yes: for what indication, and in what population? Write the population out in full, including the exclusions. This is the sentence people skip.
3. If yes: is the use you are actually interested in inside that population, or outside it? Be honest. Most readers will find at least one entry where the answer is "outside," and noticing that is the entire point of the field.
4. If no: what is it sold as, and what does that label accomplish legally? "Research use only" is not a description of quality. It is a description of jurisdiction.

Step 2 — Add the gap line

For every entry, write one line describing the distance between what is approved and how the compound is discussed. For a compound with no approval, the distance is the whole thing. For bremelanotide, the distance is a specific hormonal-status boundary and a specific diagnosis. For insulin, there is essentially no gap, and noticing which of your entries has no gap is as informative as noticing which has the largest.

Step 3 — Note what off-label means and does not mean

One clarification you will need for the rest of the book. Off-label prescribing is legal, common, and often entirely appropriate — a physician may prescribe an approved drug outside its approved indication using clinical judgment, and a great deal of good medicine works this way, particularly in pediatrics and oncology.

What off-label use does not do is generate evidence. The trials that supported the approval were run in the approved population, and they remain evidence about that population only. When you write Field 7, you are not recording whether something may be prescribed. You are recording where the evidence stops — and that boundary does not move when a prescription is written.

Conclusion

A research program set out to produce a tan without ultraviolet light, and it succeeded — and along the way it produced an approved treatment for a sexual desire disorder, an approved treatment for a rare photosensitivity disease, and an unapproved compound sold on the internet with a melanoma signal attached. All from one receptor family. All, in two cases, from nearly the same molecule.

That is not an anomaly to be marveled at. It is Chapter 2's thesis stated in its strongest available form: the melanocortin peptides have no intrinsic function. They darken skin where MC1R is expressed, suppress appetite where MC4R is expressed in the hypothalamus, and act on sexual motivation where the relevant central circuits are. Change the tissue and you change the drug without changing the molecule.

The most useful thing in this chapter, though, is probably §24.3, because it is the piece of knowledge most likely to be immediately applicable. Desire and blood flow are different problems. Vascular drugs work downstream of arousal and cannot manufacture interest. Central drugs act on the interest and do nothing for the plumbing. A person who does not know this can spend years and considerable money aiming at the wrong target and concluding, wrongly, that nothing works for them.

And the rating table is the chapter's other durable lesson. Bremelanotide's ✅ is real and it is narrow and it is modest, all at once, and holding those three facts together without letting any of them swallow the others is the discipline this whole book is trying to teach. ✅ means the evidence supports this claim in this population. It does not mean the drug is dramatic. A reader who leaves this chapter with that calibration fixed will read the remaining chapters more accurately than one who leaves with a list of which peptides are "good."

This closes Part IV. The neuropeptides and social peptides have been a part full of near-misses — molecules with gorgeous, well-characterized physiology whose translation into medicine keeps running into the same three walls: the blood-brain barrier, the difference between a pulse and a flat infusion, and the gap between changing a mechanism and changing an outcome. Bremelanotide is the one clear approval in the part, and even it arrives with a narrow label, a modest effect, and a common adverse effect that limits its practical use. That is not a discouraging note to end on. It is an accurate one, and accuracy about the difficulty is the reason the field's genuine successes are worth taking seriously when they arrive.

Chapter 25 opens Part V.

Key Terms

Melanocortin — the family of peptides derived from proopiomelanocortin, including α-MSH and ACTH, acting at the five melanocortin receptors.

Melanocortin receptor — a family of five G-protein-coupled receptors, MC1R through MC5R, differing in tissue distribution and therefore in physiological consequence.

MC1R — the melanocortin receptor on melanocytes; activation shifts pigment production and darkens skin, hair, and existing moles.

MC3R / MC4R — central nervous system melanocortin receptors involved in energy balance (Chapter 13) and in sexual function.

Alpha-melanocyte-stimulating hormone (α-MSH) — the endogenous melanocortin peptide that signals melanocytes to produce pigment and participates in central appetite regulation.

Proopiomelanocortin (POMC) — the precursor protein from which α-MSH, ACTH, and β-endorphin are cleaved; one precursor, several unrelated hormones.

Bremelanotide (PT-141) — a cyclic seven-amino-acid melanocortin receptor agonist, approved for hypoactive sexual desire disorder in premenopausal women.

Cyclic peptide — a peptide whose chain is closed into a ring, raising potency and slowing degradation.

Lactam bridge — an amide bond formed between two amino acid side chains, used here to cyclize the molecule; a chemically robust alternative to a disulfide bond.

D-amino acid — the mirror-image form of an amino acid, not used in normal human protein synthesis, incorporated deliberately in synthetic peptides to resist proteases.

Hypoactive sexual desire disorder (HSDD) — persistently low or absent sexual desire that causes marked distress or interpersonal difficulty and is not better explained by another condition, a medication, or relationship circumstances.

Distress criterion — the requirement that a condition cause distress to be diagnosed. In HSDD it is what distinguishes a disorder from ordinary variation: low desire that does not trouble the person is not a disorder.

PDE5 inhibitor — a class of small-molecule drugs (sildenafil and relatives) acting peripherally to sustain genital blood flow by preventing the breakdown of cyclic GMP.

Central versus peripheral action — whether a drug acts in the brain and spinal cord or in the tissues; the distinction that separates a desire drug from a blood-flow drug.

Validated instrument — a questionnaire whose measurement properties have been formally tested, used as a trial endpoint where no objective measure exists.

Minimal clinically important difference — the smallest change on an instrument that a patient would notice and value; the bridge between a statistically significant result and a meaningful one.

Afamelanotide (melanotan I) — an α-MSH analog with high MC1R activity, approved to increase pain-free light exposure in erythropoietic protoporphyria.

Erythropoietic protoporphyria (EPP) — a rare inherited disorder of heme synthesis causing accumulation of protoporphyrin IX and severe burning pain on exposure to visible light.

Protoporphyrin IX — the heme precursor that accumulates in EPP and generates reactive species when it absorbs visible light.

Melanotan II — an unapproved cyclic melanocortin agonist sold for cosmetic tanning; structurally closely related to bremelanotide, with greater MC1R activity.

Melanocytic nevus — a mole; a benign proliferation of melanocytes. Changes in existing nevi are among the case-report findings in melanotan II users.

Kisspeptin — a hypothalamic peptide acting through KISS1R upstream of GnRH; essential for activation of the reproductive axis.

KISS1R — the kisspeptin receptor; loss-of-function mutations cause failure of puberty.

GnRH (gonadotropin-releasing hormone) — the pituitary-stimulating hormone whose pulsatile release drives LH and FSH secretion; continuous stimulation suppresses the axis rather than activating it.

Hypogonadotropic hypogonadism — failure of the gonads secondary to inadequate upstream signaling from the hypothalamus or pituitary, rather than to a problem in the gonads themselves.

Medicalization — the process by which a human variation or difficulty comes to be described, studied, and treated as a medical condition; a description, not automatically a criticism.

Spaced Review

1. A person reports that a PDE5 inhibitor "did nothing" for them. Using §24.3, give two distinct explanations, only one of which is that the drug failed. What single question would distinguish them?

2. (Chapter 13) Setmelanotide is an MC4R agonist approved for rare genetic obesity syndromes, and it causes skin hyperpigmentation. Bremelanotide is a melanocortin agonist approved for a sexual desire disorder, and it can cause focal hyperpigmentation. Explain both observations with one sentence about receptors, and then say what this predicts about any future melanocortin-based drug.

3. (Chapter 5) A published series of case reports describes new and changing moles in melanotan II users, and separately a small case series describes remarkable recoveries in athletes using an unapproved peptide. Explain why the first set carries real evidentiary weight and the second carries almost none, using the same principle for both.

4. (Chapter 21) Part IV has repeatedly encountered peptides whose physiology is well understood and whose clinical translation has been disappointing. Name the specific obstacle that recurs across the part's molecules, and explain why bremelanotide's approval does not really constitute an exception to it.

5. Bremelanotide for HSDD in premenopausal women is ✅ and the effect is modest; melanotan II for cosmetic tanning is ❌ and is reinforced by a safety signal. Write, in your own words, what each symbol is and is not asserting — and then explain why a ⚠️ compound could in principle have a larger true effect than a ✅ one.